TRANSFORM3: Evaluation of Implementation Strategies of Teaching, Technology, and Teams to Optimize Medical Therapy in Cardiovascular Disease (T3)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 750
- 试验地点
- 2
- 主要终点
- Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record.
研究概览
简要总结
This initiative supports a quality improvement effort evaluating the use of strategies (including technology-based decision support, referral to a virtual GDMT team, and general educational tools/resources for clinicians and patients) to improve use of guideline-directed therapeutics known to lower cardiovascular (CV) events among patients with cardiovascular diseases of heart failure, atrial fibrillation and type 2 diabetes (T2D)/ASCVD with a specific focus on underserved populations and those with a history of health care disparities.
详细描述
TRANSFORM3 is a Quality Improvement initiative conducted in parallel to the current TRANSFORM CVRiD study and aligned with its goals of using a real-world population study to enable the American College of Cardiology Foundation ("ACCF") to better identify impactful ways to improve guideline directed medical therapy for patients. TRANSFORM3 is focused on improving GDMT use in underserved patients and patients with a history of health care disparities who have one or more of the following: heart failure, atrial fibrillation, and ASCVD/Type 2 diabetes.
There is a significant disconnect between increasing availability of effective and safe therapeutics that significantly reduce CV event risk in patients with Heart Failure, T2D and ASCVD, and Atrial Fibrillation-and clear guideline recommendations endorsing these therapies-but very low adoption in clinical practice with the majority of eligible patients that are most likely to benefit from these therapies not receiving them. A high proportion of patients have more than one of these conditions further reducing the chances of receiving optimal guideline directed medical therapy and avoiding the CV events they are designed to prevent.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥18 years
- •Personal access to a computer and/or Smartphone for app download
- •Heart Failure (reduced and preserved ejection fraction) AND/OR
- •Atrial Fibrillation with CHA2DS2-VASc score greater than or equal to 2 in men and greater than or equal to 3 in women AND/OR
- •T2D and ASCVD, defined as follows:
- •Known CAD, prior ACS, or coronary artery revascularization
- •Prior TIA/stroke or known carotid or intracerebral atherosclerosis
- •Prior PAD including requiring revascularization
排除标准
- •All patients
- •Current or anticipated participation in an interventional clinical trial of a drug/device
- •Currently receiving comfort care or enrolled in hospice
- •Life expectancy <1 year
- •Pregnancy or active breastfeeding
- •Current or anticipated participation in an interventional clinical trial (other than TRANSFORM3 GDMT)
- •Patients without a clinical encounter within three years of study start date
- •Heart Failure patients:
- •History of or plan for heart transplantation or left ventricular assist de-vice
- •Palliative chronic inotropic therapy
- •NYHA Class 4 heart failure
- •Atrial Fibrillation patients:
- •Current prescription for OAC
- •Reversible cause of atrial fibrillation, such as post-cardiothoracic surgery or thyrotoxicosis
- •History of ischemic stroke in prior 7 days
- •Transient ischemic attack in prior 3 days
- •Platelet count <70,000/ml
- •Hemoglobin concentration <8g/dl
- •History of or condition associated with increased bleeding risk, such as hemophilia
- •Major surgical procedure or trauma within 14 days
- •Clinically significant gastrointestinal bleeding within 8 weeks
结局指标
主要结局
Adoption of evidence-based CV-risk reduction and disease management therapies for HF, AF, and T2D/ASCVD. This data will be found in the patient's medical record.
时间窗: 9 months
GDMT baseline to 9 month change in average composite endpoint of receiving the main classes of drugs (50% or higher of target doses for HF) among eligible patients. We're aiming to see a change or increase in guideline-directed care where there was an original gap.
次要结局
- Quality of Life Outcome-PAM(Study duration up to 1 year.)
- Quality of Life Outcome-MMA-4(Study duration up to 1 year.)
- Quality of Life Outcome-KCCQ-12(Study duration up to 1 year.)